Maraviroc and Lenacapavir: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lenacapavir
Maraviroc
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects
Interaction Deep Dive
Coadministration of lenacapavir together with sensitive CYP3A substrates that are P-gp substrates may increase these substrate exposure and result in the increased risk of their adverse events. Lenacapavir may increase the exposure of drugs primarily metabolized by CYP3A, initiated within 9 months after the last dose of lenacapavir, which may also increase the potential risk of adverse reactions12.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport by lenacapavir; inhibition of CYP3A substrate metabolism by lenacapavir
Common questions
Can I take Maraviroc and Lenacapavir together?
Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Maraviroc and Lenacapavir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Maraviroc or Lenacapavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: SUNLENCA(R) oral tablets, subcutaneous injection, lenacapavir oral tablets, subcutaneous injection. Gilead Sciences Inc (per FDA), Foster City, CA, 2024. DailyMed
- Product Information: YEZTUGO(R) oral tablets, subcutaneous injection, lenacapavir oral tablets, subcutaneous injection. Gilead Sciences Inc (per manufacturer), Foster City, CA, 2025. DailyMed
Keep reading about Lenacapavir
Keep reading about Maraviroc
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist